BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 17961187)

  • 1. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.
    O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki AB; Koziner B; Chanan-Khan AA; Seymour JF; Gribben J; Itri LM; Rai KR
    J Clin Oncol; 2009 Nov; 27(31):5208-12. PubMed ID: 19738118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the diagnosis and treatment of chronic lymphocytic leukemia.
    Abbott BL
    Clin Adv Hematol Oncol; 2004 Jul; 2(7):448-54. PubMed ID: 16163221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging therapy for chronic lymphocytic leukaemia.
    Auer RL; Gribben J; Cotter FE
    Br J Haematol; 2007 Dec; 139(5):635-44. PubMed ID: 17961187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies.
    Montillo M; Hamblin T; Hallek M; Montserrat E; Morra E
    Haematologica; 2005 Mar; 90(3):391-9. PubMed ID: 15749671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status and future directions of clinical trials in chronic lymphocytic leukemia.
    Nerenstone SR; Archer JI; Cheson BD
    Oncology (Williston Park); 1987 Oct; 1(8):31-40, 44. PubMed ID: 3079490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia.
    Kharfan-Dabaja MA; Chavez JC; Khorfan KA; Pinilla-Ibarz J
    Cancer; 2008 Sep; 113(5):897-906. PubMed ID: 18618518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controversies in the front-line management of chronic lymphocytic leukemia.
    Nabhan C; Shanafelt TD; Kay NE
    Leuk Res; 2008 May; 32(5):679-88. PubMed ID: 18191201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of chronic lymphocytic leukemia.
    Faderl SJ; Keating MJ
    Curr Hematol Rep; 2005 Jan; 4(1):31-8. PubMed ID: 15610657
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.